Advisors Asset Management Inc. raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 24.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,821 shares of the medical research company’s stock after buying an additional 3,504 shares during the period. Advisors Asset Management Inc. owned 0.06% of Bio-Rad Laboratories worth $4,033,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of BIO. Teacher Retirement System of Texas raised its stake in shares of Bio-Rad Laboratories by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after buying an additional 29 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Bio-Rad Laboratories by 2.3% in the second quarter. Arizona State Retirement System now owns 8,800 shares of the medical research company’s stock worth $1,992,000 after buying an additional 200 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Bio-Rad Laboratories by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 115,218 shares of the medical research company’s stock worth $26,075,000 after buying an additional 2,070 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth $113,000. Finally, Trexquant Investment LP acquired a new stake in shares of Bio-Rad Laboratories during the second quarter worth $308,000. Hedge funds and other institutional investors own 63.66% of the company’s stock.
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 212.43 on Friday. The firm has a 50-day moving average price of $228.17 and a 200 day moving average price of $213.43. The company has a market capitalization of $6.30 billion, a P/E ratio of 419.82 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 12-month low of $147.68 and a 12-month high of $242.79.
Several equities research analysts recently weighed in on BIO shares. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Jefferies Group LLC restated a “buy” rating and set a $275.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target on the stock. Finally, Deutsche Bank AG upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price target for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $228.80.
In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.29% of the stock is currently owned by company insiders.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
